J. Drenth

发表

Premenstrual syndrome predicts alcohol craving in women with substance use disorders

C. D. De Jong, Rouhollah Qurishi, J. Drenth, 2022, Women & health.

for the Induction of Cytokine Release Domain-2 Modulates Specific TLR Pathways Nucleotide-Binding Oligomerization

L. Jacobs, M. Netea, S. Girardin, 2005 .

Hyperimmunoglobulinemia D and Periodic Fever Syndrome: The Clinical Spectrum in a Series of 50 Patients

J. V. D. van der Meer, C. Haagsma, J. Drenth, 1994, Medicine.

A SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION METHOD FOR W MEASUREMENT OF MRNA FOR TNF-oc AND IL-ip IN WHOLE BLOOD CULTURES: ITS APPLICATION IN TYPHOID FEVER AND EXENTRIC EXERCISE

E. Dharmana, J. Drenth, 2017 .

ERYTHROMELALGIA AND ERYTHERMALGIA: LUMPERS AND SPLITTERS

J. Michiels, J. Drenth, 1994, International journal of dermatology.

ERYTHROMELALGIA AND ERYTHERMALGIA: DIAGNOSTIC DIFEERENTIATION

J. Michiels, J. Drenth, 1994, International journal of dermatology.

Restrictive strategy versus usual care for cholecystectomy in patients with gallstones and abdominal pain (SECURE): a multicentre, randomised, parallel-arm, non-inferiority trial

M. Boermeester, M. Dijkgraaf, J. Heisterkamp, 2019, The Lancet.

Efficacy of colchicine in familial Mediterranean fever is well established

J. Drenth, 1996, BMJ.

Erythromelalgia Versus Primary and Secondary Erythermalgia

J. Michiels, J. Drenth, 1994, Angiology.

Treatment options in primary erythermalgia?

J. Michiels, J. Drenth, 1993, American journal of hematology.

Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.

J. Drenth, G. di Perri, R. van Crevel, 2016, AIDS.

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.

J. Drenth, C. Gluud, M. H. Lamers, 2014, The Cochrane database of systematic reviews.

Biochemical Effects on the Liver of 1 Month of Alcohol Abstinence in Moderate Alcohol Consumers

D. Swinkels, J. Drenth, A. Schellekens, 2018, Alcohol and alcoholism.

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations

M. van der Valk, R. D. de Knegt, H. Reesink, 2014, Clinical Pharmacokinetics.

Sodium channel genes in pain-related disorders: phenotype–genotype associations and recommendations for clinical use

C. Woods, S. Dib-Hajj, S. Waxman, 2014, The Lancet Neurology.

CONFERENCE: Hyperimmunoglobulinaemia D syndrome

J. Drenth, RichardJ. Powell, 1995 .

Elective Switching from Infliximab to Adalimumab in Stable Crohn's Disease

D. D. de Jong, J. Drenth, F. Hoentjen, 2013, Inflammatory bowel diseases.

Thrombocythemic erythromelalgia, primary erythermalgia, and secondary erythermalgia: three distinct clinicopathologic entities.

P. V. van Genderen, J. Drenth, J. Michiels, 1994, Angiology.

Buerger's disease and antiphospholipid syndrome

J. Drenth, 2004 .

Buerger's disease and antiphospholipid syndrome urgent specific treatment.

J. Drenth, 2004 .

Defining endpoints that guide treatment in autoimmune hepatitis.

T. Gevers, M. Heneghan, J. Drenth, 2022, Journal of hepatology.

Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease

J. M. van de Kamp, M. Breuning, E. Tahvanainen, 2004, Hepatology.

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

M. Wouthuyzen-Bakker, A. Colbers, O. El-sherif, 2019 .

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon‐alfa‐2a and ribavirin for chronic hepatitis C

R. D. de Knegt, C. Weegink, B. Hansen, 2011, Alimentary pharmacology & therapeutics.

Hereditary periodic fever and reactive amyloidosis

J. Drenth, A. Simon, J. C. H. Hilst, 2005, Clinical and Experimental Medicine.

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat

J. Drenth, D. Burger, C. D. de Kanter, 2017, The Journal of antimicrobial chemotherapy.

Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis.

J. Drenth, J. Jansen, R. T. Morsche, 2001, Gut.

AL amyloidosis enhances development of amyloid A amyloidosis

J. Meer, A. Simon, J. Drenth, 2007, The British journal of dermatology.

Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.

J. Meer, A. Vonk, R. Powell, 2001, The Journal of pharmacology and experimental therapeutics.

Multiple authorship: the contribution of senior authors.

J. Drenth, J P Drenth, J. Drenth, 1998, JAMA.

Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?

A. Dall'aglio, W. V. van Venrooij, F. Bianchi, 2006, Annals of the rheumatic diseases.

Elevated serum level and altered glycosylation of alpha 1-acid glycoprotein in hyperimmunoglobulinemia D and periodic fever syndrome: evidence for persistent inflammation.

J. V. D. van der Meer, J. van der Meer, E. C. van Ommen, 1995, Clinical immunology and immunopathology.

Genetic linkage of the Muckle-Wells syndrome to chromosome 1q44.

J. Beckmann, D. Scott, David Steven Scott, 1999, American journal of human genetics.